RK

Raj Kumar

Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organisation, Indian Institute of Technology Roorkee

ORCID iD 0000-0002-9702-2788
Follow

About

I joined the Institute of Nuclear Medicine and Allied Sciences (INMAS), DRDO in the year 2001 just after completing my Ph.D. in biotechnology from the Indian Institute of Technology, Roorkee. INMAS is a premier institution that worked in the area of radiation countermeasure development. I start learning about radioprotection and its importance, its national and international importance, etc. During the initial phase of my learning, I thought about radioresistant bacteria and their possible applications in the area of radioprotector development. I discussed my interest with INMAS director Dr. R.P Tripathi. He not only appreciates my logic but rather gave me a task project to initiate work in this novel area in the year 2005. since then I involved in the same area and achieved several milestones. As a result of the continuous support from my organization, I have identified the bioactive bacterial molecules that provide excellent radioprotection to the cells, mice, and Non-human primates (Monkey). This molecule has been qualified for its regulatory toxicity/safety profile, stable and efficacious human usable formulation, pharmacokinetics studies, pharmaceutical targets, and efficacy biomarker and validation studies. This molecule may be the first Indian molecule that will reach the IND status and emergency use approval from the regulatory authorities of India. Recently we received a new grant from my organization (DRDO) to conduct all regulatory studies and get the IND status for this molecule. Hopefully, we will be successful in this endeavor in near future.

Employment

  • Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organisation Scientist-F
    2001 - 2031

Education

  • Indian Institute of Technology Roorkee Ph.D.
    1995 - 2000

Projects & Funding

  • Development of Advance products and technologies for medical management of CBRN emeregencies specific to R&N incidents-An integrated Approach (No. TD-22-23/INM-328) Cost 22.00 Crore DRDO
    2022 - 2025
  • “Development of harbal radioprotective drug for human applications” Sponsored by DRDO DRDO
  • “Evaluation of radio-resistant bacteria for radioprotector development” Sponsored by DRDO (Total Cost: INR:10.0 Lakhs) DRDO
  • Development of radioprotective drug from radio-resistant bacteria for prophylactic and therapeutic applications” Sponsored by DRDO under 11th, five year plan Govt. of India (Total Cost: 2.45 Crore) DRDO
  • 4. Development of Radiation Countermeasures Using Radioresistant Bacteria Against Radiological Emergency (No. TD-15/INM-313/1.2); Cost 4.41 Crore DRDO
  • 5. Development of radioprotector for minimizing radiation induced adverse health effects in humans (No. TD-15/INM-313/1.1); Cost: 16.55 Crore DRDO
  • 6. Identification of Proteomic/Genomic Biomarkers of Blast/Shock Wave Induced Traumatic Brain Injuries. Cost: 1.5 Crore. (India-USA collaborative project) DRDO
  • 7. Indo-USA joint collaborative project entitled “Development of traumatic brain Injuries predictive model for assessment of injuries caused by blast wave/blunt wave”. Sponsored by DRDO, Govt. of India and Ministry of Defence Govt. of India and Departmen… DRDO

Publications (109)